Medicines Patent Pool Takes Novel Approach With Roche In Valcyte Deal
This article was originally published in PharmAsia News
Executive Summary
Roche and the Medicines Patent Pool have signed a five-year deal that will allow developing countries to achieve faster access to the Swiss company’s CMV drug, Valcyte for 90% less.
You may also be interested in...
Patent Rebuff For Roche’s Valcyte In India, Again
Roche’s powder formulation for Valcyte (valganciclovir) has failed to secure a patent in India, at least for now, with the patent office seeing no ‘technical advancement’ in the invention.
AIDS Patent Pool Garners Support From Industry, But Pharma Companies Want Flexibility In Pricing Between Countries
The drug purchasing group UNITAID may succeed in getting pharmaceutical companies to pool patents on their AIDS medicines. So far, it has won buy-in of the idea from three: Gilead Sciences, Merck and Johnson & Johnson subsidiary Tibotec
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.